Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

被引：49
|
作者：
Rolston, Kenneth V. I. [1 ]
Gerges, Baghat [1 ]
Shelburne, Samuel [1 ]
Aitken, Samuel L. [2 ]
Raad, Issam [1 ]
Prince, Randall A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 05期
关键词：
Gram-negative isolates; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; cefiderocol; VITRO ANTIMICROBIAL ACTIVITY; SIDEROPHORE CEPHALOSPORIN; S-649266;
D O I：
10.1128/AAC.01955-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at <= 4 mg/liter. It had potent activity against extended-spectrum beta-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae. No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France (vol 3, pg 390, 2021)
    Naas, Thierry
    Lina, Gerard
    Henriksen, Anne Santerre
    Longshaw, Christopher
    Jehl, Francois
    JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 (03):
  • [32] IN VITRO ACTIVITY OF CEFIDEROCOL AGAINST GRAM-NEGATIVE BACTERIA ISOLATED FROM BURN PATIENTS
    Nguyen, Sean
    Dejonge, Boudewijn
    Bryowsky, Jason
    Maher, Joshua
    Mendes, Rodrigo
    Longshaw, Christopher
    Takemura, Miki
    Yamano, Yoshinori
    CRITICAL CARE MEDICINE, 2025, 53 (01)
  • [33] Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe
    Sader, Helio S.
    Carvalhaes, Cecilia G.
    Duncan, Leonard R.
    Shortridge, Dee
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [34] In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates from Respiratory Specimens: SIDERO-WT-2014
    Yamano, Y.
    Tsuji, M.
    Echols, R.
    Hackel, M.
    Sahm, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [35] In Vitro Activity Of Ceftaroline And Comparators Against Staphylococcus aureus Isolates: Results From 6 Years Of The ATLAS Program (2012 To 2017)
    Zhang, Zhijie
    Chen, Meng
    Yu, Ying
    Liu, Beini
    Liu, Yong
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 3349 - 3358
  • [36] In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019-2020
    Kuraieva, Alona
    Cabezas-Camarero, Guillermo
    Kiratisin, Pattarachai
    Utt, Eric
    ANTIBIOTICS-BASEL, 2023, 12 (08):
  • [37] Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
    Shortridge, Dee
    Deshpande, Lalitagauri M.
    Streit, Jennifer M.
    Castanheira, Mariana
    JAC-ANTIMICROBIAL RESISTANCE, 2022, 4 (05):
  • [38] Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
    Petropoulou, Dimitra
    Siopi, Maria
    Vourli, Sophia
    Pournaras, Spyros
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
  • [39] COMPARATIVE INVITRO ACTIVITY OF CEFPIROME AND OTHER ANTIMICROBIAL AGENTS AGAINST ISOLATES FROM CANCER-PATIENTS
    ROLSTON, K
    ALVAREZ, ME
    HOY, JF
    LEBLANC, B
    HO, DH
    BODEY, GP
    CHEMOTHERAPY, 1986, 32 (04) : 344 - 351
  • [40] In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020
    Hawser, Stephen
    Kothari, Nimmi
    Monti, Federica
    Morrissey, Ian
    Siegert, Sherry
    Hodges, Tony
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 33 : 304 - 320
12345